Literature DB >> 27034396

Preclinical Mouse Models for Analysis of the Therapeutic Potential of Engineered Oncolytic Herpes Viruses.

Maria-Carmela Speranza1, Kazue Kasai1, Sean E Lawler1.   

Abstract

After more than two decades of research and development, oncolytic herpes viruses (oHSVs) are moving into the spotlight due to recent encouraging clinical trial data. oHSV and other oncolytic viruses function through direct oncolytic cancer cell-killing mechanisms and by stimulating antitumor immunity. As further viruses are developed and optimized for the treatment of various types of cancer, appropriate predictive preclinical models will be of great utility. This review will discuss existing data in this area, focusing on the mouse tumor models that are commonly used.
© The Author 2016. Published by Oxford University Press on behalf of the Institute for Laboratory Animal Research. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2016        PMID: 27034396      PMCID: PMC4816123          DOI: 10.1093/ilar/ilw002

Source DB:  PubMed          Journal:  ILAR J        ISSN: 1084-2020


  86 in total

Review 1.  Oncolytic viruses and their application to cancer immunotherapy.

Authors:  E Antonio Chiocca; Samuel D Rabkin
Journal:  Cancer Immunol Res       Date:  2014-04       Impact factor: 11.151

2.  Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.

Authors:  Ryuichi Kanai; Cecile Zaupa; Donatella Sgubin; Slawomir J Antoszczyk; Robert L Martuza; Hiroaki Wakimoto; Samuel D Rabkin
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

Review 3.  The two faces of interferon-γ in cancer.

Authors:  M Raza Zaidi; Glenn Merlino
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

4.  Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.

Authors:  W R Jarnagin; J S Zager; M Hezel; S F Stanziale; P S Adusumilli; M Gonen; M I Ebright; A Culliford; N J Gusani; Y Fong
Journal:  Cancer Gene Ther       Date:  2006-03       Impact factor: 5.987

Review 5.  How genetically engineered mouse tumor models provide insights into human cancers.

Authors:  Katerina Politi; William Pao
Journal:  J Clin Oncol       Date:  2011-01-24       Impact factor: 44.544

Review 6.  Overcoming current limitations in humanized mouse research.

Authors:  Michael A Brehm; Leonard D Shultz; Jeremy Luban; Dale L Greiner
Journal:  J Infect Dis       Date:  2013-11       Impact factor: 5.226

7.  Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47.

Authors:  K Ahn; T H Meyer; S Uebel; P Sempé; H Djaballah; Y Yang; P A Peterson; K Früh; R Tampé
Journal:  EMBO J       Date:  1996-07-01       Impact factor: 11.598

8.  Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Authors:  Hiroaki Wakimoto; Santosh Kesari; Christopher J Farrell; William T Curry; Cecile Zaupa; Manish Aghi; Toshihiko Kuroda; Anat Stemmer-Rachamimov; Khalid Shah; Ta-Chiang Liu; Deva S Jeyaretna; Jason Debasitis; Jan Pruszak; Robert L Martuza; Samuel D Rabkin
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

9.  Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector.

Authors:  U Herrlinger; C M Kramm; K S Aboody-Guterman; J S Silver; K Ikeda; K M Johnston; P A Pechan; R F Barth; D Finkelstein; E A Chiocca; D N Louis; X O Breakefield
Journal:  Gene Ther       Date:  1998-06       Impact factor: 5.250

Review 10.  Oncolytic viruses: a new class of immunotherapy drugs.

Authors:  Howard L Kaufman; Frederick J Kohlhapp; Andrew Zloza
Journal:  Nat Rev Drug Discov       Date:  2015-09       Impact factor: 84.694

View more
  5 in total

Review 1.  Pouring petrol on the flames: Using oncolytic virotherapies to enhance tumour immunogenicity.

Authors:  Alicia Teijeira Crespo; Stephanie Burnell; Lorenzo Capitani; Rebecca Bayliss; Elise Moses; Georgina H Mason; James A Davies; Andrew J Godkin; Awen M Gallimore; Alan L Parker
Journal:  Immunology       Date:  2021-03-28       Impact factor: 7.215

2.  oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity.

Authors:  Wen Zhang; Xiao Hu; Jing Liang; Yujie Zhu; Beibei Zeng; Lin Feng; Changyun Zhao; Shangmei Liu; Binlei Liu; Kaitai Zhang
Journal:  Mol Ther Oncolytics       Date:  2020-01-11       Impact factor: 7.200

3.  The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer.

Authors:  Liesa-Marie Schreiber; Carles Urbiola; Krishna Das; Bart Spiesschaert; Janine Kimpel; Fabian Heinemann; Birgit Stierstorfer; Philipp Müller; Monika Petersson; Patrik Erlmann; Dorothee von Laer; Guido Wollmann
Journal:  Br J Cancer       Date:  2019-09-18       Impact factor: 7.640

4.  Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability.

Authors:  Faith Howard; Joe Conner; Sarah Danson; Munitta Muthana
Journal:  Front Mol Biosci       Date:  2022-06-15

5.  Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses.

Authors:  Erkko Ylösmäki; Cristina Malorzo; Cristian Capasso; Oona Honkasalo; Manlio Fusciello; Beatriz Martins; Leena Ylösmäki; Antti Louna; Sara Feola; Henrik Paavilainen; Karita Peltonen; Veijo Hukkanen; Tapani Viitala; Vincenzo Cerullo
Journal:  Mol Ther       Date:  2018-06-19       Impact factor: 11.454

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.